Levetiracetam
Product Images NDC 14335-050

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 14335-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hainan Poly Pharm. Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (01)

A bar chart comparing the percentage of patients for placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 3,000 mg/day groups. The y-axis represents the percentage of patients (0% to 45%). The placebo group has 7.4%, Levetiracetam 1,000 mg/day has 37.1%, and Levetiracetam 3,000 mg/day has 39.6%. Sample sizes are shown below each group label.*

FDA Label Image

Figure 2 (02)

A bar chart comparing the percentage of patients among three groups: Placebo (N=111) at 6.3%, Levetiracetam 1,000 mg/day (N=106) at 20.8%, and Levetiracetam 2,000 mg/day (N=105) at 35.2%. The vertical axis shows the percentage of patients from 0% to 45%, and the chart highlights increased patient percentages with higher doses of Levetiracetam.*

FDA Label Image

Figure 3 (03)

A bar chart comparing the percentage of patients (%) between two groups: Placebo (N=104) at 14.4% and Levetiracetam 3,000 mg/day (N=180) at 39.4%. The y-axis shows patient percentage from 0% to 45%, highlighting a statistically significant difference marked by an asterisk (*) over the Levetiracetam bar.*

FDA Label Image

Figure 4 (04)

A bar graph comparing the percentage of patients in two groups: Placebo (N=97) with 19.6% and Levetiracetam (N=101) with 44.6%. The y-axis represents the percentage of patients ranging from 0% to 45%. An asterisk is shown within the Levetiracetam bar.*

FDA Label Image

Figure 5 (05)

A bar chart comparing the percentage of patients between a placebo group (19.6%) and a Levetiracetam group (43.1%). The vertical axis represents the percentage of patients from 0% to 45%, with the placebo group having 51 patients and the Levetiracetam group having 58 patients. A statistical significance marker (*) is shown above the Levetiracetam bar.*

FDA Label Image

Figure 6 (06)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The Placebo group shows 45.2% of patients, while the Levetiracetam group shows 72.2% of patients. The y-axis represents the percentage of patients ranging from 0% to 100%.*

FDA Label Image

Principal Display Panel (100 mg/mL Vial Carton)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) single-dose vials. The package contains 10 vials of 5 mL each. It is for intravenous use only and must be diluted prior to administration. The product is sterile and labeled for Rx only. Manufacturer is Hainan Poly Pharm. Co., Ltd., with storage instructions and contact information included.*

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of Levetiracetam depicting its molecular arrangement including a pyrrolidone ring attached to a methyl and an amide group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.